modelL01XK05
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Veliparib | |
| ATC code: | L01XK05 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 113 | L |
| clearance: | 26.6 | L/h |
| other parameters in model implementation | ||
Veliparib (ATC code L01XK05) is a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, used primarily in oncology as a targeted therapy for cancers such as ovarian and breast cancer, particularly in patients with BRCA mutations. Veliparib is not broadly approved as a monotherapy but has been investigated in combination with DNA-damaging chemotherapies in clinical trials.
Pharmacokinetics
Pharmacokinetic parameters in adult patients with advanced solid tumors (mainly ovarian or BRCA-associated breast cancer) after single oral administration, median age 54, mixed sex.
References
Singh, R, et al., & Beumer, JH (2019). Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer chemotherapy and pharmacology 83(2) 319–328. DOI:10.1007/s00280-018-3731-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30456480
Stodtmann, S, et al., & Xiong, H (2021). A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients. Journal of clinical pharmacology 61(9) 1195–1205. DOI:10.1002/jcph.1875 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33894017
Salem, AH, et al., & Mostafa, NM (2014). Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies. Clinical pharmacokinetics 53(5) 479–488. DOI:10.1007/s40262-013-0130-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24452810
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)